Literature DB >> 30127900

Screening and identification of key biomarkers in bladder carcinoma: Evidence from bioinformatics analysis.

Meiqin Yan1, Xuan Jing2, Yina Liu1, Xiangrong Cui3.   

Abstract

Bladder cancer (BC) is one of the most common urogenital malignancies. However, present studies of its multiple gene interaction and cellular pathways remain unable to accurately verify the genesis and the development of BC. The aim of the present study was to investigate the genetic signatures of BC and identify its potential molecular mechanisms. The gene expression profiles of GSE31189 were downloaded from the Gene Expression Omnibus database. The GSE31189 dataset contained 92 samples, including 52 BC and 40 non-cancerous urothelial cells. To further examine the biological functions of the identified differentially expressed genes (DEGs), Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) enrichment analyses were performed, and a protein-protein interaction (PPI) network was mapped using Cytoscape software. In total, 976 DEGs were identified in BC, including 457 upregulated genes and 519 downregulated genes. GO and KEGG pathway enrichment analyses indicated that upregulated genes were significantly enriched in the cell cycle and the negative regulation of the apoptotic process, while the downregulated genes were mainly involved in cell proliferation, cell adhesion molecules and oxidative phosphorylation pathways (P<0.05). From the PPI network, the 12 nodes with the highest degrees were screened as hub genes; these genes were involved in certain pathways, including the chemokine-mediated signaling pathway, fever generation, inflammatory response and the immune response nucleotide oligomerization domain-like receptor signaling pathway. The present study used bioinformatics analysis of gene profile datasets and identified potential therapeutic targets for BC.

Entities:  

Keywords:  bladder cancer; differentially expressed genes; microarray analysis; protein-protein interaction network

Year:  2018        PMID: 30127900      PMCID: PMC6096082          DOI: 10.3892/ol.2018.9002

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


Introduction

Bladder cancer (BC), the most frequently occurring urogenital malignancy of the urinary tract worldwide, results in substantial morbidity and mortality (1,2). In the USA, bladder cancer is the fourth most common cancer, with 76,960 estimated new cases and 16,390 mortalities in 2016 (3). In addition to other carcinoma types, such as cervical (4), prostate (5) and ovarian cancer (6), the accumulation of inherited and somatic mutations in oncogenes and tumor suppressor genes are believed to be the reason for the occurrence, progression and metastasis of BC (7–9). Although a number of cancer-associated genes and cellular pathways have been proven to be associated with the initiation and development of BC (10,11), the accuracy of early diagnosis, therapeutic and prognostic evaluation for BC remains low. Consequently, investigating the molecular mechanisms, including the proliferation, apoptosis and invasion of BC is crucial for the progress of diagnostic and treatment strategies. With the development of gene microarray technology, various advanced techniques for assessing gene expression have been widely applied in assessing tumor development and progression with lower expenses, compared with past decades (12,13). In previous years, numerous gene expression profiling studies on BC have revealed hundreds of differentially expressed genes (DEGs) and provided substantial functional information on gene regulatory network analysis (14–16). However, comparative analysis of DEGs reported by independent research appears to rarely display substantial overlap (17), and no reliable biomarker profile discriminating cancerous from non-cancerous samples has been identified. At present, due to bioinformatics methods, the data generated by microarray technology have been analyzed in order to identify mRNA expression changes in collected urothelial cells and to examine DEGs in BC and non-cancerous urothelial cells (18). However, the interactions among DEGs, particularly pathways in the interaction network, remain to be elucidated. In the present study, original data (data set GSE31189) were downloaded from the Gene Expression Omnibus (GEO) (19), in order to identify DEGs between BC and non-cancerous urothelial cells. Then, functional annotation and network analyses were performed to identify DEGs. By analyzing the biological functions and networks of BC, the present study may be useful to gain a better understanding of BC development at a molecular level and explore the potential candidate biomarkers for diagnosis, prognosis and treatment.

Materials and methods

Data source

The GSE31189 gene expression profile and its corresponding platform annotation files were downloaded from the GEO database. This data set was submitted by Professor Virginia Urquidi on 3rd August 2011, last updated on 21st April 2017 and stockpiled on the GPL570 platform (HG-U133_Plus_2) Affymetrix Human Genome U133 Plus 2.0 Array (Affymetrix; Thermo Fisher Scientific, Inc., Waltham, MA, USA). This gene expression data consisted of the data of 92 samples, including 52 BC and 40 non-cancerous urothelial cells.

Data preprocessing and screening of DEGs

The probes without annotation of the gene expression profiles were filtered using the Affy package (20), which is based on the Bioconductor principles of reproducibility, transparency and efficiency of development (21). The probe ID for each gene was then transformed into a gene symbol using the Affymetrix Human Genome U133 Plus 2.0 Array annotation data (hgu133plus2.db) and Genome wide annotation for Human, version: 3.7 (org. Hs.eg.db) packages from Bioconductor (http://www.bioconductor.org/). For a gene symbol corresponding to multiple probe IDs, the average value of these probes was calculated as the representative expression level of this gene. The DEGs were screened by using the Linear Models for Microarray Analysis package in R software (R ×64 3.3.3) (22) with cut-off criteria of P<0.05 and |log2 fold-change (FC)|>0.5.

Functional annotation and pathway enrichment

Gene Ontology analysis (GO) is a common useful approach for annotating genes and gene products and for identifying characteristic biological phenomena for high-throughput genome or transcriptome data (23,24). To describe gene product attributes, GO provides three categories of defined terms, including biological process (BP), cellular component (CC) and molecular function (MF) categories (25). Kyoto Encyclopedia of Genes and Genomes (KEGG) is an integrated database resource for the systematic analysis of gene functions, linking genomic information with higher-order functional information (26). The two analyses were available in the Database for Annotation, Visualization and Integrated Discovery (DAVID; https://david.ncifcrf.gov/; date of access, 8/02/2018), which is a bioinformatics data resource composed of an integrated biology knowledge base and analysis tools to extract biological meanings from large quantities of genes and protein collections through a novel agglomeration algorithm (27). In the present study, GO term analysis and KEGG pathway analysis were performed using the DAVID online tool. P<0.05 was set as the cut-off criterion.

PPI network construction and analysis of modules

Search Tool for the Retrieval of Interacting Genes (STRING) database (http://string-db.org/) is an online software designed to assess protein-protein interaction (PPI) information, including direct (physical) and indirect (functional) associations (28). In the present study, the DEGs were mapped using STRING to evaluate the PPI information with a combined score of >0.4 set as the cut-off criterion. Then, the PPI network was visualized using Cytoscape 3.5.0 (29). To screen the hub genes, a node degree of ≥10 was selected as the threshold. Furthermore, the Molecular Complex Detection (MCODE) plug-in was used to screen modules of hub genes from the PPI network with degree threshold=10, haircut on, node score cut-off=0.2, k-core=2 and maximum depth=100 (30). The genes in the significant modules were further mapped to GO terms and KEGG pathways for functional analysis.

PrognoScan database analysis

The overall survival (OS) rate of mRNA expression was assessed using an online database, PrognoScan (http://www.abren.net/PrognoScan/; keywords: NOD2, S100A9, CXCL1, CXCR2; date of access, 8/02/2018), which is a platform used for evaluating potential tumor markers and therapeutic targets. To evaluate the OS rate of patients with breast cancer, patient samples were divided into two groups by median expression [high vs. low expression; Threshold: NOD (0.87), S100A9 (0.77), CXCL1 (0.68), CXCR2 (0.55)] and analyzed using PrognoScan, with a hazard ratio with 95% confidence intervals and Cox's Proportional-Hazards Model.

Results

Data processing and DEG screening

With a criteria of the false discovery ratio <0.05 and |log2 FC|≥0.571, a total of 976 DEGs (when compared with those of the noncancerous urothelial cells) were identified in the BC samples, including 457 upregulated genes and 519 downregulated genes (Fig. 1).
Figure 1.

DEG analysis of the GSE31189 data set. DEGs were identified using the Linear Models for Microarray Analysis package. Blue indicates downregulated genes, red indicates upregulated genes and black indicates genes with unchanged expression. DEG, differentially expressed gene; FC, fold-change; down, downregulated; no, no change; up, upregulated.

Functional enrichment of DEGs

DAVID analysis was performed to predict the potential functions and mechanisms of BC by mapping the upregulated and downregulated genes using GO terms and the KEGG pathways. The top five significant GO terms of the BP, CC and MF categories enriched by the up- and downregulated DEGs were identified (Figs. 2 and 3). The results demonstrated that the upregulated genes were mainly involved in the negative regulation of the apoptotic process in the BP category, constituted integral components of the plasma membrane in the CC category, and were mainly involved in protein binding in the MF category (Fig. 2), whereas the downregulated genes were mainly associated with cell proliferation in the BP category, were mainly intracellular in the CC category, and were mainly involved in metal ion binding in the MF category (Fig. 3). The results for the KEGG pathway enrichment are shown in Fig. 4, which indicated that the upregulated genes were significantly enriched in amoebiasis, malaria, osteoclast differentiation, Legionellosis, Chagas disease, advanced glycation end product-receptor for AGE signaling pathway in diabetic complications, salmonella infection, toxoplasmosis, tumor necrosis factor (TNF) signaling pathway and rheumatoid arthritis pathways, while the downregulated genes were mainly enriched in cell adhesion molecules, oxidative phosphorylation, taurine and hypotaurine metabolism, collecting duct acid secretion, vitamin digestion and absorption, rheumatoid arthritis and vibrio cholerae infection pathways.
Figure 2.

GO analysis of upregulated genes of the GSE31189 data set. GO, Gene Ontology; MF, molecular function; CC, cellular component; BP, biological process.

Figure 3.

GO analysis of downregulated genes of the GSE31189 data set. GO, Gene Ontology; MF, molecular function; CC, cellular component; BP, biological process.

Figure 4.

KEGG pathway enrichment analysis. KEGG, Kyoto Encyclopedia of Genes and Genomes; BP, biological process; CC, cellular component; TNF, tumor necrosis factor; AGE-RAGE, advanced glycation end product-receptor for AGE.

Construction of a PPI network and functional analysis for key genes

The Cytoscape tool visually constructed the PPI network with 98 nodes and 321 edges, which were predicted using STRING with a PPI score of >0.4 (Fig. 5). In the PPI network, 28 nodes with a degree of ≥10 were regarded as key genes (Table I), including interleukin (IL)-1B, matrix metalloproteinase (MMP)9, heat shock protein family A (Hsp70) member 6, FGR proto-oncogene, Src family tyrosine kinase, ribosomal protein S6 kinase A1, TNF receptor superfamily member 1A, RAS-like family 11 member B, MMP1, chemokine ligand (CCL)5, C-X-C motif chemokine receptor 2 (CXCR2), C-X-C motif chemokine ligand 1 (CXCL1), Pim-1 proto-oncogene, serine/threonine kinase, nucleotide binding oligomerization domain containing 2 (NOD2), CCL20, src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites, serine threonine kinase 21B, S100 calcium binding protein A9 (S100A9), Kruppel-like factor 8, phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 β, cluster of differentiation 83, renin, G protein subunit α 15, transporter 1, ATP binding cassette subfamily B member, secretory leukocyte peptidase inhibitor, NME/NM23 family member 5, BCS homolog, ubiquinol-cytochome c reductase complex chaperone, cell division cycle 20 and NME/NM23 nucleoside diphosphate kinase 3. One module including 12 nodes and 62 edges was obtained using MCODE (Fig. 6). The heat map indicated that the 12 genes were able to distinguish the two groups of cell samples, in that their expression was distinctly different between the two groups (Fig. 7). GO term enrichment analysis demonstrated that in the BP category, the genes in this module were significantly involved in the chemokine-mediated signaling pathway, fever generation, inflammatory responses, immune responses and the positive regulation of cell division (Table II). The genes were significantly enriched in the CC category were significantly part of the extracellular space, autophagosome, cytoplasmic vesicle, extracellular matrix and lysosome (Table II). Finally, in the MF category, analysis revealed that the genes were mainly associated with chemokine activity, IL-1 receptor binding, C-C motif receptor chemokine receptor, cytokine activity and metalloendopeptidase activity (Table II). KEGG analysis revealed that the genes were mainly enriched in the TNF signaling pathway, rheumatoid arthritis, prion diseases, cytokine-cytokine receptor interaction and NOD-like receptor signaling pathway (Table II).
Figure 5.

Protein-protein interaction network of differentially expressed genes. Red nodes denote upregulated genes, green nodes denote downregulated genes.

Table I.

Key nodes in the protein-protein interaction network with a degree ≥10.

GeneDegree of changeLog2 fold-change
IL-1B231.211413
MMP9220.762970
HSPA6201.198230
FGR180.674802
RPS6KA118−0.692775
TNFRSF1A170.601014
RASL11B16−0.600296
MMP1150.743885
CCL515−0.698948
CXCR2150.988178
CXCL1151.088843
PIM1140.686538
NOD2140.633431
CCL20140.677125
SRMS13−0.619940
STK21B13−0.598366
S100A9131.202516
KLF813−0.585851
PIK3c2B12−0.604130
CD83120.801585
REN12−0.737372
GNA15120.647069
TAP1111.004478
SLPI111.064963
NME511−0.905805
BCS1L10−0.621588
CDC20100.646275
NME310−0.709424
Figure 6.

One significant module selected from the protein-protein interaction network. Red nodes denote upregulated genes, green nodes denote downregulated genes.

Figure 7.

Hub genes expression heat map in the GSE31189 data set. Red indicates upregulation and green indicates downregulation.

Table II.

Functional and pathway enrichment analysis of the genes in the module.

CategoryTermCount%P-value
GO BPGO:0070098-chemokine-mediated signaling pathway340.41.09×10−04
GO_BPGO:0001660-fever generation227.02.00×10−03
GO_BPGO:0006954-inflammatory response340.43.14×10−03
GO_BPGO:0006955-immune response340.43.21×10−03
GO_BPGO:0051781-positive regulation of cell division227.05.48×10−03
GO_CCGO:0005615-extracellular space547.41.86×10−04
GO_CCGO:0005776-autophagosome227.01.67×10−02
GO_CCGO:0031410-cytoplasmic vesicle227.03.19×10−02
GO_CCGO:0031012-extracellular matrix227.03.66×10−02
GO_CCGO:0005764-lysosome227.04.73×10−02
GO_MFGO:0008009-chemokine activity340.41.16×10−04
GO_MFGO:0005149-interleukin-1 receptor binding227.04.78×10−03
GO_MFGO:0048020-C-C motif receptor chemokine receptor binding227.01.01×10−02
GO_MFGO:0005125-cytokine activity227.04.28×10−02
GO_MFGO:0004222-metalloendopeptidase activity227.04.95×10−02
KEGG_PATHWAYecb04668: Tumor necrosis factor signaling pathway680.94.39×10−09
KEGG_PATHWAYecb05323: Rheumatoid arthritis567.43.04×10−07
KEGG_PATHWAYecb05020: Prion diseases340.43.42×10−04
KEGG_PATHWAYecb04060: Cytokine-cytokine receptor interaction453.95.48×10−04
KEGG_PATHWAYecb04621: Nucleotide oligomerization domain-like receptor signaling pathway340.48.04×10−04

GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function; KEGG, Kyoto Encyclopedia of Genes and Genomes. The count was the number of enriched genes in each term. If there were >5 terms enriched in this category, the top five terms were selected according to their P-value.

Association between 12 key genes and prognosis in patients with BC

The PrognoScan database was used to perform the association analysis of mRNA expression and OS rate in patients with BC. As presented in Table III and Fig. 8, the high expression of NOD2 (P<0.05), S100A9 (P<0.001), CXCL1 (P<0.05) and CXCR2 (P<0.01) were significantly associated with a poor prognosis in patients with BC.
Table III.

Association between mRNA expression of enriched genes and overall survival in patients with bladder cancer.

Gene nameEnd pointPROBE IDnCox P-valueHazard ratio
CCL5Overall survival rateILMN_17733521650.1124591.2
SLPIOverall survival rateILMN_16696501650.2256931.09
S100A9Overall survival rateILMN_17149911650.0001191.28
CXCL1Overall survival rateILMN_17878971650.0138031.23
TNFRSF1AOverall survival rateILMN_16850051650.7324441.08
CCL20Overall survival rateILMN_16572341650.6363720.95
MMP1Overall survival rateILMN_17264481650.2797561.07
NOD2Overall survival rateILMN_17625941650.0250391.45
IL1BOverall survival rateILMN_17755011650.3746881.10
CXCR2Overall survival rateILMN_17830851650.0060800.59
CD83Overall survival rateILMN_17805821650.1699561.27
MMP1Overall survival rateILMN_17963161650.1140521.15
Figure 8.

Association between mRNA expression and overall survival rate in patients with bladder cancer (using the PrognoScan database). P<0.05 was used as the threshold. NOD2, nucleotide binding oligomerization domain containing 2; S100A9, S100 calcium binding protein A9; CXCL1, C-X-C motif chemokine ligand 1; CXCR2, C-X-C motif chemokine receptor 2; HR, hazard ratio.

Discussion

BC is the ninth most common genitourinary malignancy, globally and resulted in 165,000 mortalities in 2012 (31–33). Understanding the molecular mechanism of BC is of great importance for diagnosis and treatment. Due to well-developed microarray and high-throughput sequencing technology, it is now easier to determine the general genetic alterations in the progression of diseases, and has been widely adopted to predict potential diagnosis and therapeutic targets for BC (34). In the present study, data were extracted from the GSE31189 dataset and 457 upregulated and 519 downregulated DEGs between BC and normal control specimens were identified using bioinformatics analysis. The upregulated genes were enriched in the negative regulation of apoptotic processes and the positive regulation of cell division, while the downregulated genes were mainly involved in cell proliferation, bicellular tight junction, mitochondrial matrix and immune responses. Furthermore, by constructing the PPI, a number of key genes were identified that may be useful in future therapeutic studies on BC. Notably, key nodes in the PPI network and genes in the significant modules, including NOD2, S100A9, CXCL1 and CXCR2, may have specific contributions to the occurrence and development of BC. The NOD2 gene, a member of the evolutionarily conserved Nod-like receptors family, is located on chromosome 16q21 (35,36). Wang et al revealed that the abnormal expression of NOD2 was highly expressed in primary liver tumor types, which was associated with a shorter median survival time (36). In addition, in the present study, a higher NOD2 mRNA expression was identified in BC, which was associated with a shorter OS rate. S100A9, a member of the S100 family of calcium-binding proteins, is primarily detected in neutrophil granulocytes and known to serve a function in the innate immune system (37,38). Previous studies have demonstrated that the abnormal overexpression of S100A9 is an unfavorable prognostic factor for carcinogenesis and prognosis in various neoplasms, such as hypopharyngeal and bladder cancer (39–43). Additionally, S100A9 is associated with colorectal carcinoma progression and contributes to colorectal carcinoma cell survival and migration via the Wnt/β-catenin pathway (37). In the present study, S100A9 was revealed to be differentially expressed in BC and non-cancerous urothelial cells and was identified as a key node in the PPI network constructed using DEGs between these two groups. The results additionally demonstrated that a high S100A9 expression was associated with a shorter OS rate. Therefore, this gene may be an essential marker for the diagnosis and prognosis of BC. CXCL1, a member of the CXC chemokine family, was originally characterized by Wang et al (44) and is known to promote the proliferation of melanoma cells. Previous studies have demonstrated that CXCL1 may be associated with tumor epithelial-stromal interactions that facilitate tumor growth and invasion (45–47). In addition, Wang et al (48) revealed that CXCL1 derived from tumor-associated lymphatic endothelial cells drives gastric cancer cells into the lymphatic system by activating integrin β1/focal adhesion kinase/protein kinase B (Akt) signaling. Furthermore, Kawanishi et al (49) revealed that CXCL1 may modulate the invasive abilities of BC cells, and therefore is a potential candidate biomarker and therapeutic target for invasive BC. In the present study, a higher CXCL1 mRNA expression was identified in patients with BC in the GSE31189 gene expression profile. Furthermore, PrognoScan analysis results revealed that high CXCL1 expression was significantly associated with a shorter OS rate. Due to these findings, the expression level of CXCL1 may be a useful prognostic marker of BC. CXCR2, the co-receptor of IL-8 and CXCL1, is an important therapeutic target in a number of solid tumor types, including lung, breast, prostate, ovarian, colorectal and liver cancer (50–55). Xu et al (56) revealed that CXCR2 may promote breast cancer metastasis and chemoresistance via the suppression of AKT serine/threonine kinase 1 and activation of cyclooxygenase 2. Inhibition of CXCR2 may reduce the activity of breast cancer stem cells and improve the survival of human epidermal growth factor receptor 2 (HER2)-positive patients in combination with HER2-target chemotherapies (57). Furthermore, Gao et al (58) demonstrated that the CXCL5/CXCR2 axis may promote BC cell migration and invasion by activating the phosphoinositide 3-kinase/Akt-induced upregulation of MMP2/MMP9. In the present study, CXCR2 was increased in BC compared with normal specimens, similar with the previous studies. However, the BC patients with higher mRNA levels of CXCR2 were predicted to have a better OS rate. As few studies have focused on CXCR2, the underlying function of CXCR2 requires further research. Altogether, the DEGs identified in the BC urothelial cells when compared with the normal controls may be involved in tumorigenesis. The key nodes identified in the PPI network constructed with these DEGs and genes involved in the significant module, including NOD2, S100A9 and CXCL1, may be important in the development of BC, and may provide valuable clues in order to investigate the pathogenesis of BC. However, further biological experimental evidence is required in order to confirm the function of the identified gene in BC.
  58 in total

1.  IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer.

Authors:  Q Yang; X Li; H Chen; Y Cao; Q Xiao; Y He; J Wei; J Zhou
Journal:  Oncogene       Date:  2017-01-16       Impact factor: 9.867

2.  Identification of candidate genes for necrotizing enterocolitis based on microarray data.

Authors:  Guanglin Chen; Yang Li; Yang Su; Lingling Zhou; Hua Zhang; Qiyang Shen; Chunxia Du; Hongxing Li; Zechao Wen; Yankai Xia; Weibing Tang
Journal:  Gene       Date:  2018-03-29       Impact factor: 3.688

3.  DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Authors:  David S Wishart; Craig Knox; An Chi Guo; Savita Shrivastava; Murtaza Hassanali; Paul Stothard; Zhan Chang; Jennifer Woolsey
Journal:  Nucleic Acids Res       Date:  2006-01-01       Impact factor: 16.971

4.  Loss of β-arrestin-2 and Activation of CXCR2 Correlate with Lymph Node Metastasis in Non-small Cell Lung Cancer.

Authors:  Lei Cong; Zhi-Yong Qiu; Yang Zhao; Wei-Bo Wang; Cai-Xia Wang; Hong-Chang Shen; Jun-Qing Han
Journal:  J Cancer       Date:  2017-08-23       Impact factor: 4.207

5.  Overexpression of CXCR2 predicts poor prognosis in patients with colorectal cancer.

Authors:  Jingkun Zhao; Baochi Ou; Hao Feng; Puxiongzhi Wang; Shuai Yin; Congcong Zhu; Shenjie Wang; Chun Chen; Minhua Zheng; Yaping Zong; Jing Sun; Aiguo Lu
Journal:  Oncotarget       Date:  2017-04-25

6.  Systematic analysis of gene expression alterations and clinical outcomes of STAT3 in cancer.

Authors:  Xiangrong Cui; Xuan Jing; Qin Yi; Chunlan Long; Bin Tan; Xin Li; Xueni Chen; Yue Huang; Zhongping Xiang; Jie Tian; Jing Zhu
Journal:  Oncotarget       Date:  2017-12-14

7.  S100A8 and S100A9 are associated with colorectal carcinoma progression and contribute to colorectal carcinoma cell survival and migration via Wnt/β-catenin pathway.

Authors:  Liang Duan; Rui Wu; Liwei Ye; Haiyan Wang; Xia Yang; Yunyuan Zhang; Xian Chen; Guowei Zuo; Yan Zhang; Yaguang Weng; Jinyong Luo; Min Tang; Qiong Shi; Tongchuan He; Lan Zhou
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240

8.  CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.

Authors:  Bharat Devapatla; Ankur Sharma; Sukyung Woo
Journal:  PLoS One       Date:  2015-09-28       Impact factor: 3.240

9.  Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers.

Authors:  Makito Miyake; Adrienne Lawton; Steve Goodison; Virginia Urquidi; Evan Gomes-Giacoia; Ge Zhang; Shanti Ross; Jeongsoon Kim; Charles J Rosser
Journal:  BMC Cancer       Date:  2013-07-01       Impact factor: 4.430

10.  The long non-coding RNA CCAT2 is up-regulated in ovarian cancer and associated with poor prognosis.

Authors:  Shuying Huang; Cheng Qing; Zikun Huang; Yuanfang Zhu
Journal:  Diagn Pathol       Date:  2016-06-10       Impact factor: 2.644

View more
  1 in total

1.  Intersectin 1 (ITSN1) identified by comprehensive bioinformatic analysis and experimental validation as a key candidate biological target in breast cancer.

Authors:  Chen Xie; Wenmin Xiong; Junyu Li; Xia Wang; Chen Xu; Liping Yang
Journal:  Onco Targets Ther       Date:  2019-08-30       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.